[{"innerBlocks":[],"name":"core\/freeform","postId":482,"blockType":{"name":"core\/freeform","keywords":[],"attributes":{"content":{"type":"string","source":"raw"},"lock":{"type":"object"}},"providesContext":[],"usesContext":[],"selectors":[],"supports":{"className":false,"customClassName":false,"reusable":false},"styles":[],"variations":[],"apiVersion":3,"title":"Classic","description":"Use the classic WordPress editor.","category":"text"},"originalContent":"Danville, Penn.-based Geisinger is teaming with tech vendor Tempus to leverage artificial intelligence for the development of diagnostic and prognostic tools for cardiovascular disease.Under the multi-year partnership, the two organizations are looking to use machine learning to predict life-threatening cardiac events so that clinicians have the opportunity to intervene before it is too late.\u201cOur mission is to improve the lives of patients with cardiovascular disease through the development and application of state-of-the-art technologies,\u201d says Brandon Fornwalt, MD, co-director of the Cardiac Imaging and Technology Laboratory at Geisinger, a group of engineers, researchers and physician scientists within the Department of Imaging Science and Innovation. The collaboration, which will be housed within Geisinger\u2019s Cardiac Imaging and Technology Laboratory, will tap into Tempus\u2019 proprietary machine learning platform which will analyze the health system\u2019s vast clinical database to identify outcome and response data leading to more proactive cardiovascular treatments and interventions.

\u201cGeisinger has a long history of innovation when it comes to assembling novel datasets to improve patient care,\u201d says Eric Lefkofsky, founder and CEO of Tempus. \u201cWe are thrilled to be collaborating with them to bring the power of technology and artificial intelligence to cardiology.\u201dTempus, which works with almost 50 National Cancer Institute-designated cancer centers, has been focused on oncology but is looking to expand to precision medicine solutions for patients with cardiovascular disease through the partnership with Geisinger.Last year, the company announced the launch of a new mobile app\u2014Tempus Labs--that enables physicians to securely access structured clinical information, a dynamic view of their patient\u2019s molecular alterations, potential therapies, as well as relevant clinical trial options.\u201cTempus is one of the best in the business at building and translating these kinds of technologies, so we are very excited to work with them,\u201d adds Fornwalt. \u201cThis collaboration brings together complementary areas of expertise unified behind a joint vision of integrating the best technology available to positively impact our patients."","saveContent":"Danville, Penn.-based Geisinger is teaming with tech vendor Tempus to leverage artificial intelligence for the development of diagnostic and prognostic tools for cardiovascular disease.Under the multi-year partnership, the two organizations are looking to use machine learning to predict life-threatening cardiac events so that clinicians have the opportunity to intervene before it is too late.\u201cOur mission is to improve the lives of patients with cardiovascular disease through the development and application of state-of-the-art technologies,\u201d says Brandon Fornwalt, MD, co-director of the Cardiac Imaging and Technology Laboratory at Geisinger, a group of engineers, researchers and physician scientists within the Department of Imaging Science and Innovation. The collaboration, which will be housed within Geisinger\u2019s Cardiac Imaging and Technology Laboratory, will tap into Tempus\u2019 proprietary machine learning platform which will analyze the health system\u2019s vast clinical database to identify outcome and response data leading to more proactive cardiovascular treatments and interventions.

Geisinger, Tempus to build precision medicine tools for cardiology

More for you